NIKKEI 225
27,885.87 +65.47 (+0.24%) HANG SENG
19,441.18 -77.11 (-0.40%) CRUDE OIL
74.33 -2.60 (-3.38%) GOLD FUTURES
1,783.30 +2.00 (+0.11%) DOW
33,608.25 -338.85 (-1.00%) BTC-GBP
13,997.61 -26.11 (-0.19%)
SENS Jan 2024 5.000 call
| Previous close | 0.1000 |
| Open | 0.1100 |
| Bid | 0.0700 |
| Ask | 0.1000 |
| Strike | 5.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.1000 - 0.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.69k |
- Business Wire
Senseonics to Present at the Stifel 2022 Healthcare Conference
GERMANTOWN, Md., November 09, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel Healthcare Conference in New York, NY.
- Business Wire
Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results
GERMANTOWN, Md., November 08, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2022.
- Business Wire
Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)
GERMANTOWN, Md., November 03, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® CGM Systems, today announced the launch of a collaboration with the Nurse Pr
